4D Pharma restates first-half earnings due to accounting change

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 97%

Business News News

Business Business Latest News,Business Business Headlines

The London- and U.S.-listed pharmaceutical company said the warrants and units should be recorded as derivative liabilities and not equity instruments under...

A previously published version of this story incorrectly stated that 4D’s loss widened in the first paragraph, and numbers were transposed in the fourth and fifth paragraphs. The story has been corrected.

The... A previously published version of this story incorrectly stated that 4D’s loss widened in the first paragraph, and numbers were transposed in the fourth and fifth paragraphs. The story has been corrected. The London- and U.S.-listed pharmaceutical company LBPS DDDD said the warrants and units should be recorded as derivative liabilities and not equity instruments under both IFRS and U.S. GAAP accounting standards.Under the change, pretax loss for the half year ended June 30 was 50.1 million pounds compared with a previously reported loss of GBP57.0 million and a loss of GBP15.7 million for the comparable half.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in BUSİNESS

Business Business Latest News, Business Business Headlines